203 related articles for article (PubMed ID: 35027594)
1. Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs.
Maeda S; Sakai K; Kaji K; Iio A; Nakazawa M; Motegi T; Yonezawa T; Momoi Y
Sci Rep; 2022 Jan; 12(1):4. PubMed ID: 35027594
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumour effect of lapatinib in canine transitional cell carcinoma cell lines.
Sakai K; Maeda S; Saeki K; Nakagawa T; Murakami M; Endo Y; Yonezawa T; Kadosawa T; Mori T; Nishimura R; Matsuki N
Vet Comp Oncol; 2018 Dec; 16(4):642-649. PubMed ID: 30246405
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladder.
Greene SN; Lucroy MD; Greenberg CB; Bonney PL; Knapp DW
J Am Vet Med Assoc; 2007 Oct; 231(7):1056-60. PubMed ID: 17916030
[TBL] [Abstract][Full Text] [Related]
4. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
5. Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.
Mohammed SI; Craig BA; Mutsaers AJ; Glickman NW; Snyder PW; deGortari AE; Schlittler DL; Coffman KT; Bonney PL; Knapp DW
Mol Cancer Ther; 2003 Feb; 2(2):183-8. PubMed ID: 12589035
[TBL] [Abstract][Full Text] [Related]
6. Epidermal Growth Factor Receptor Family Inhibition Identifies P38 Mitogen-activated Protein Kinase as a Potential Therapeutic Target in Bladder Cancer.
Mora Vidal R; Regufe da Mota S; Hayden A; Markham H; Douglas J; Packham G; Crabb SJ
Urology; 2018 Feb; 112():225.e1-225.e7. PubMed ID: 29154981
[TBL] [Abstract][Full Text] [Related]
7. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F
Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417
[TBL] [Abstract][Full Text] [Related]
8. Piroxicam, mitoxantrone, and coarse fraction radiotherapy for the treatment of transitional cell carcinoma of the bladder in 10 dogs: a pilot study.
Poirier VJ; Forrest LJ; Adams WM; Vail DM
J Am Anim Hosp Assoc; 2004; 40(2):131-6. PubMed ID: 15007049
[TBL] [Abstract][Full Text] [Related]
9. Toxic effects and antitumor response of gemcitabine in combination with piroxicam treatment in dogs with transitional cell carcinoma of the urinary bladder.
Marconato L; Zini E; Lindner D; Suslak-Brown L; Nelson V; Jeglum AK
J Am Vet Med Assoc; 2011 Apr; 238(8):1004-10. PubMed ID: 21492043
[TBL] [Abstract][Full Text] [Related]
10. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
Tevaarwerk AJ; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract transitional cell carcinoma in dogs.
Allstadt SD; Rodriguez CO; Boostrom B; Rebhun RB; Skorupski KA
J Vet Intern Med; 2015 Jan; 29(1):261-7. PubMed ID: 25619518
[TBL] [Abstract][Full Text] [Related]
12. Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.
Powles T; Huddart RA; Elliott T; Sarker SJ; Ackerman C; Jones R; Hussain S; Crabb S; Jagdev S; Chester J; Hilman S; Beresford M; Macdonald G; Santhanam S; Frew JA; Stockdale A; Hughes S; Berney D; Chowdhury S
J Clin Oncol; 2017 Jan; 35(1):48-55. PubMed ID: 28034079
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma.
Henry CJ; McCaw DL; Turnquist SE; Tyler JW; Bravo L; Sheafor S; Straw RC; Dernell WS; Madewell BR; Jorgensen L; Scott MA; Higginbotham ML; Chun R
Clin Cancer Res; 2003 Feb; 9(2):906-11. PubMed ID: 12576466
[TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacokinetics of tyrosine kinase inhibitor, lapatinib, in dogs and cats following single oral administration.
Yu TW; Yamamoto H; Morita S; Fukushima R; Elbadawy M; Usui T; Sasaki K
J Vet Med Sci; 2024 Mar; 86(3):317-321. PubMed ID: 38281758
[TBL] [Abstract][Full Text] [Related]
15. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
Larbouret C; Gaborit N; Chardès T; Coelho M; Campigna E; Bascoul-Mollevi C; Mach JP; Azria D; Robert B; Pèlegrin A
Neoplasia; 2012 Feb; 14(2):121-30. PubMed ID: 22431920
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.
Johnston SR; Leary A
Drugs Today (Barc); 2006 Jul; 42(7):441-53. PubMed ID: 16894399
[TBL] [Abstract][Full Text] [Related]
17. EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas.
Cooper O; Bonert VS; Rudnick J; Pressman BD; Lo J; Salvatori R; Yuen KCJ; Fleseriu M; Melmed S
J Clin Endocrinol Metab; 2021 Jan; 106(2):e917-e925. PubMed ID: 33150390
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of carbon dioxide laser ablation combined with mitoxantrone and piroxicam treatment in dogs with transitional cell carcinoma.
Upton ML; Tangner CH; Payton ME
J Am Vet Med Assoc; 2006 Feb; 228(4):549-52. PubMed ID: 16478428
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer.
Agelaki S; Kalykaki A; Markomanolaki H; Papadaki MA; Kallergi G; Hatzidaki D; Kalbakis K; Mavroudis D; Georgoulias V
PLoS One; 2015; 10(6):e0123683. PubMed ID: 26083256
[TBL] [Abstract][Full Text] [Related]
20. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
Guo XF; Zhu XF; Zhong GS; Deng BG; Gao ZT; Wang H
Oncol Rep; 2012 May; 27(5):1639-45. PubMed ID: 22293713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
